TY - JOUR
T1 - The development of an implantable deep brain stimulation device with simultaneous chronic electrophysiological recording and stimulation in humans
AU - Goyal, Abhinav
AU - Goetz, Steve
AU - Stanslaski, Scott
AU - Oh, Yoonbae
AU - Rusheen, Aaron E.
AU - Klassen, Bryan
AU - Miller, Kai
AU - Blaha, Charles D.
AU - Bennet, Kevin E.
AU - Lee, Kendall
N1 - Funding Information:
Recently, a fully-implantable clinical DBS system with both chronic electrophysiological recording and stimulating capabilities has been approved by the Food and Drug Administration (FDA) for DBS lead implantation into the subthalamic nucleus (STN) and ventral intermediate nucleus of the thalamus (VIM). Herein, the engineering underlying the development of the Percept PC device, device specifications, and design choices are outlined, including hardware and software specifications. Percept PC stimulation is current-controlled. This ensures consistent and accurate current delivery to the target, and is relatively insensitive to changes in impedance at the electrode-tissue interface, which have resulted in fluctuating current delivery from traditional voltage-controlled stimulation devices (Lempka et al., 2010; Miocinovic et al., 2009). During LFP recording, it utilizes a 10 μA current from a 2 V supply and achieves a relatively low noise floor (150 nV/Hz). Design choices implemented within the signal recording pipeline afford high resolution, nearly-simultaneous recording and stimulation while also reducing noise and stimulation artifact. Recordings proceed continuously in the presence of stimulation with short blanking periods to prevent elements of the stimulation artifact from interrupting the otherwise contiguous measure of brain state. The system contains 16 stimulation channels and 6 recording channels. Taking advantage of CMOS technology ensures that the recording amplifier integrated circuit generates low noise and requires low static power consumption, allowing the device to support the digital signal processing algorithms required for accurate LFP recording. The device's ability and functionality to chronically record LFPs at implanted DBS leads was validated in 14 patients with neurological disorders.
Publisher Copyright:
© 2020
PY - 2021/3/15
Y1 - 2021/3/15
N2 - Deep brain stimulation (DBS) is used to treat a wide array of neurologic conditions. However, traditional programming of stimulation parameters relies upon short term subjective observation of patient symptoms and undesired stimulation effects while in the clinic. To gain a more objective measure of the neuronal activity that contributes to patient symptoms and response to treatment, there is a clear need for a fully-implantable DBS system capable of chronically recording patient-specific electrophysiological biomarker signals over time. By providing an objective correlate of a patient's disease and response to treatment, this capability has the potential to improve therapeutic benefit while preventing undesirable side effects. Herein, the engineering and capabilities of the Percept PC, the first FDA-approved, fully-implantable DBS device capable of nearly-simultaneous electrophysiological recordings and stimulation, are discussed. The device's ability to chronically record local field potentials (LFPs) at implanted DBS leads was validated in patients with neurological disorders. Lastly, the electrophysiological activity correlates of clinically relevant patient-reported events are presented. While FDA approved for conditions such as Parkinson's disease, essential tremor, dystonia, obsessive-compulsive disorder, and epilepsy, chronic electrophysiological recordings in humans has broad applications within basic science and clinical practice beyond DBS, offering a wealth of information related to normal and abnormal neurophysiology within distinct brain areas.
AB - Deep brain stimulation (DBS) is used to treat a wide array of neurologic conditions. However, traditional programming of stimulation parameters relies upon short term subjective observation of patient symptoms and undesired stimulation effects while in the clinic. To gain a more objective measure of the neuronal activity that contributes to patient symptoms and response to treatment, there is a clear need for a fully-implantable DBS system capable of chronically recording patient-specific electrophysiological biomarker signals over time. By providing an objective correlate of a patient's disease and response to treatment, this capability has the potential to improve therapeutic benefit while preventing undesirable side effects. Herein, the engineering and capabilities of the Percept PC, the first FDA-approved, fully-implantable DBS device capable of nearly-simultaneous electrophysiological recordings and stimulation, are discussed. The device's ability to chronically record local field potentials (LFPs) at implanted DBS leads was validated in patients with neurological disorders. Lastly, the electrophysiological activity correlates of clinically relevant patient-reported events are presented. While FDA approved for conditions such as Parkinson's disease, essential tremor, dystonia, obsessive-compulsive disorder, and epilepsy, chronic electrophysiological recordings in humans has broad applications within basic science and clinical practice beyond DBS, offering a wealth of information related to normal and abnormal neurophysiology within distinct brain areas.
KW - Bioelectronics
KW - Bioengineering
KW - Biosensing
KW - Deep brain stimulation
KW - Electrophysiological sensing
KW - Implantables
KW - Local field potentials
UR - http://www.scopus.com/inward/record.url?scp=85098657429&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85098657429&partnerID=8YFLogxK
U2 - 10.1016/j.bios.2020.112888
DO - 10.1016/j.bios.2020.112888
M3 - Article
C2 - 33395569
AN - SCOPUS:85098657429
SN - 0956-5663
VL - 176
JO - Biosensors and Bioelectronics
JF - Biosensors and Bioelectronics
M1 - 112888
ER -